抗药性癫痫市场－全球产业规模、份额、趋势、机会和预测（按治疗类型、最终用户、地区和竞争细分，2020 年至 2030 年）

2024 年全球抗药性癫痫市场价值为 18.5 亿美元，预计到 2030 年将达到 24.4 亿美元，预测期内年复合成长率(CAGR) 为 4.72%。在强大的研发活动的推动下，该市场不断发展，致力于满足对传统抗癫痫药物 (AED) 反应不足的患者未满足的需求。

癫痫是一种以反覆发作为特征的神经系统疾病，影响全球大量人口。抗药性癫痫（也称为难治性癫痫）是指患者儘管使用两种或两种以上适当的抗癫痫药物治疗，但仍会继续癫痫发作的病例。该领域代表着大量未满足的临床需求，推动全球市场格局的创新和投资。

关键市场驱动因素

癫痫盛行率不断上升

主要市场挑战

复杂且异质性的疾病概况

主要市场趋势

神经影像技术的进步

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：全球抗药性癫痫市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依治疗类型（神经调节疗法、抗癫痫药物、苯二氮平类药物、切除性癫痫手术、特定代谢治疗、特定基因治疗、免疫疗法）
  • 按最终使用者（医院和诊所、门诊护理中心、其他）
  • 按地区
  • 按公司分类（2024）
• 市场地图
  • 按治疗类型
  • 按最终用户
  • 按地区

第五章：亚太地区抗药性癫痫市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 按治疗类型
  • 按最终用户
  • 按国家/地区
• 亚太地区：国家分析
  • 中国
  • 印度
  • 澳洲
  • 日本
  • 韩国

第六章：欧洲抗药性癫痫市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 法国
  • 德国
  • 西班牙
  • 义大利
  • 英国

第七章：北美抗药性癫痫市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 墨西哥
  • 加拿大

第八章：南美洲抗药性癫痫市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第九章：中东和非洲抗药性癫痫市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第十章：市场动态

• 驱动程式
• 挑战

第 11 章：市场趋势与发展

• 最新动态
• 产品发布
• 併购

第 12 章：全球抗药性癫痫市场：SWOT 分析

第 13 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 14 章：竞争格局

• UCB SA
• Jazz Pharmaceuticals
• LivaNova PLC
• NeuroPace, Inc
• Avenue Therapeutics
• Xenon Pharmaceuticals Inc.
• Marinus Pharmaceuticals
• PTC Therapeutics
• Aquestive Therapeutics
• Neuroelectrics

第 15 章：策略建议

第16章调查会社について・免责事项

Global Drug-Resistant epilepsy market was valued at USD 1.85 billion in 2024 and is projected to reach USD 2.44 billion by 2030, registering a compound annual growth rate (CAGR) of 4.72% during the forecast period. This market continues to evolve, driven by robust research and development activities focused on addressing the unmet needs of patients who exhibit inadequate response to conventional anti-epileptic drugs (AEDs).

Epilepsy, a neurological condition characterized by recurrent seizures, affects a significant global population. Drug-resistant epilepsy-also known as refractory epilepsy-refers to cases in which patients continue to experience seizures despite treatment with two or more appropriate AEDs. This segment represents a substantial unmet clinical need, propelling innovation and investment across the global market landscape.

Key Market Drivers

Increasing Prevalence of Epilepsy

The rising global incidence of epilepsy is a primary factor fueling market growth. According to the World Health Organization (WHO), approximately 50 million individuals worldwide are affected by epilepsy. Of this population, an estimated 30% do not respond adequately to standard anti-seizure therapies, resulting in drug-resistant forms of the disorder.

As global demographics shift toward an aging population, the overall prevalence of epilepsy is expected to rise, contributing to an increased burden of drug-resistant cases. This trend underscores the urgent need for advanced therapeutic solutions tailored to this difficult-to-treat patient group.

Additionally, while up to 70% of epilepsy patients could potentially achieve seizure control with appropriate treatment, approximately 75% of individuals in low-income regions lack access to essential medications. This treatment gap highlights the critical importance of early diagnosis, improved access to care, and continued innovation in therapeutic options designed specifically for drug-resistant epilepsy.

Key Market Challenges

Complex and Heterogeneous Disease Profile

One of the most significant challenges in treating drug-resistant epilepsy is the condition's complex and heterogeneous nature. The disorder comprises a wide range of seizure types, each with distinct etiologies, clinical presentations, and treatment responses. This variability complicates efforts to develop universally effective therapies.

The evolving nature of drug-resistant epilepsy further contributes to its clinical complexity. Seizure patterns and drug efficacy may change over time, requiring continuous reassessment and adaptation of treatment strategies. As a result, the development of standardized interventions remains a major hurdle, necessitating a more personalized approach to care.

Key Market Trends

Advancements in Neuroimaging Technologies

Innovations in neuroimaging are significantly enhancing diagnostic and therapeutic capabilities in the drug-resistant epilepsy market. These advanced imaging techniques are transforming clinical approaches by providing deeper insights into brain structure and function.

Modern Magnetic Resonance Imaging (MRI) technologies-including functional MRI (fMRI), diffusion tensor imaging (DTI), and magnetic resonance spectroscopy (MRS)-offer high-resolution views of brain activity, connectivity, and subtle structural abnormalities. These tools are instrumental in identifying epileptic foci and guiding surgical or targeted treatment options.

Positron Emission Tomography (PET) also plays a crucial role by detecting metabolic irregularities in brain regions associated with seizure activity. Enhanced by advanced radiotracers and image processing methods, PET imaging facilitates more accurate diagnosis and localization of epileptic zones.

In addition, Single-Photon Emission Computed Tomography (SPECT) is widely used to assess cerebral blood flow during seizures, helping clinicians pinpoint seizure origins and inform personalized treatment planning. Collectively, these advancements are fostering a more precise and effective management paradigm for drug-resistant epilepsy.

Key Market Players

• UCB S.A.
• Jazz Pharmaceuticals
• LivaNova PLC
• NeuroPace, Inc
• Avenue Therapeutics
• Xenon Pharmaceuticals Inc.
• Marinus Pharmaceuticals
• PTC Therapeutics
• Aquestive Therapeutics
• Neuroelectrics

Report Scope:

In this report, the Global Drug-Resistant Epilepsy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Drug-Resistant Epilepsy Market, By Treatment Type:

• Neuromodulation Therapy
• Antiseizure Medications
• Benzodiazepines
• Resective Epilepsy Surgery
• Specific Metabolic Treatment
• Specific Genetic Treatment
• Immunotherapy

Drug-Resistant Epilepsy Market, By End User:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Drug-Resistant Epilepsy Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Drug-Resistant Epilepsy Market.

Available Customizations:

Global Drug-Resistant Epilepsy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Drug-Resistant Epilepsy Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Treatment Type (Neuromodulation Therapy, Antiseizure Medications, Benzodiazepines, Resective Epilepsy Surgery, Specific Metabolic Treatment, Specific Genetic Treatment, Immunotherapy)
  • 4.2.2. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 4.2.3. By Region
  • 4.2.4. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Treatment Type
  • 4.3.2. By End User
  • 4.3.3. By Region

5. Asia Pacific Drug-Resistant Epilepsy Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment Type
  • 5.2.2. By End User
  • 5.2.3. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Drug-Resistant Epilepsy Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Treatment Type
      • 5.3.1.2.2. By End User
  • 5.3.2. India Drug-Resistant Epilepsy Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Treatment Type
      • 5.3.2.2.2. By End User
  • 5.3.3. Australia Drug-Resistant Epilepsy Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Treatment Type
      • 5.3.3.2.2. By End User
  • 5.3.4. Japan Drug-Resistant Epilepsy Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Treatment Type
      • 5.3.4.2.2. By End User
  • 5.3.5. South Korea Drug-Resistant Epilepsy Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Treatment Type
      • 5.3.5.2.2. By End User

6. Europe Drug-Resistant Epilepsy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment Type
  • 6.2.2. By End User
  • 6.2.3. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Drug-Resistant Epilepsy Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment Type
      • 6.3.1.2.2. By End User
  • 6.3.2. Germany Drug-Resistant Epilepsy Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment Type
      • 6.3.2.2.2. By End User
  • 6.3.3. Spain Drug-Resistant Epilepsy Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment Type
      • 6.3.3.2.2. By End User
  • 6.3.4. Italy Drug-Resistant Epilepsy Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Treatment Type
      • 6.3.4.2.2. By End User
  • 6.3.5. United Kingdom Drug-Resistant Epilepsy Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Treatment Type
      • 6.3.5.2.2. By End User

7. North America Drug-Resistant Epilepsy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment Type
  • 7.2.2. By End User
  • 7.2.3. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Drug-Resistant Epilepsy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment Type
      • 7.3.1.2.2. By End User
  • 7.3.2. Mexico Drug-Resistant Epilepsy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment Type
      • 7.3.2.2.2. By End User
  • 7.3.3. Canada Drug-Resistant Epilepsy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment Type
      • 7.3.3.2.2. By End User

8. South America Drug-Resistant Epilepsy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment Type
  • 8.2.2. By End User
  • 8.2.3. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Drug-Resistant Epilepsy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment Type
      • 8.3.1.2.2. By End User
  • 8.3.2. Argentina Drug-Resistant Epilepsy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment Type
      • 8.3.2.2.2. By End User
  • 8.3.3. Colombia Drug-Resistant Epilepsy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment Type
      • 8.3.3.2.2. By End User

9. Middle East and Africa Drug-Resistant Epilepsy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment Type
  • 9.2.2. By End User
  • 9.2.3. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Drug-Resistant Epilepsy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment Type
      • 9.3.1.2.2. By End User
  • 9.3.2. Saudi Arabia Drug-Resistant Epilepsy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment Type
      • 9.3.2.2.2. By End User
  • 9.3.3. UAE Drug-Resistant Epilepsy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment Type
      • 9.3.3.2.2. By End User

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Drug-Resistant Epilepsy Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. UCB S.A.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Current Capacity Analysis
  • 14.1.5. Financials (In case of listed)
  • 14.1.6. Recent Developments
  • 14.1.7. SWOT Analysis
• 14.2. Jazz Pharmaceuticals
• 14.3. LivaNova PLC
• 14.4. NeuroPace, Inc
• 14.5. Avenue Therapeutics
• 14.6. Xenon Pharmaceuticals Inc.
• 14.7. Marinus Pharmaceuticals
• 14.8. PTC Therapeutics
• 14.9. Aquestive Therapeutics
• 14.10. Neuroelectrics

15. Strategic Recommendations

16. About Us & Disclaimer